Parexel's Alberto Grignolo on patient engagement: from tokenism to telling contributions

25 July 2016

Having spent 24 years working closely with pharma companies and regulators for one of the industry’s leading contract research organizations (CROs), Alberto Grignolo is highly qualified to talk about trends in the sector and the impact of changes on drug development.

Some such changes, such as the growing difficulty of obtaining remuneration for innovative drugs from payers, might be creating challenges and uncertainty for the sector, but another observation which he can make has a wholly positive influence on the industry.

This is the increasing attempt being made by companies to engage with patients at all stages of drug development to find out what they really want from products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK